Heyu Biological Technology Corporation
HYBT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,867 | $2,676 | $79 | $96 |
| % Growth | 7.1% | 3,289.4% | -18.2% | – |
| Cost of Goods Sold | $2,685 | $2,606 | $27 | $30 |
| Gross Profit | $182 | $69 | $52 | $66 |
| % Margin | 6.3% | 2.6% | 65.3% | 68.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $561 | $539 | $317 | $0 |
| SG&A Expenses | $559 | $539 | $317 | $1 |
| Sales & Mktg Exp. | -$2 | -$0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $559 | $539 | $317 | $229 |
| Operating Income | -$377 | -$470 | -$266 | -$163 |
| % Margin | -13.2% | -17.6% | -336.6% | -168.8% |
| Other Income/Exp. Net | -$117 | $25 | $0 | -$0 |
| Pre-Tax Income | -$495 | -$445 | -$266 | -$163 |
| Tax Expense | -$22 | $66 | -$0 | $0 |
| Net Income | -$472 | -$379 | -$265 | -$163 |
| % Margin | -16.5% | -14.2% | -336.1% | -169% |
| EPS | -0.001 | -0.001 | -0 | -0 |
| % Growth | -12.5% | -166.7% | -50% | – |
| EPS Diluted | -0.001 | -0.001 | -0 | -0 |
| Weighted Avg Shares Out | 518,831 | 450,232 | 103,247 | 103,247 |
| Weighted Avg Shares Out Dil | 518,831 | 450,232 | 103,247 | 103,247 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $34 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $228 | $237 |
| EBITDA | -$377 | -$470 | -$266 | -$163 |
| % Margin | -13.1% | -17.6% | -336.6% | -168.8% |